An open-label phase I study to evaluate the pharmacokinetics and safety profile of Bay 94-9027, a PEGylated B-domain-deleted recombinant factor VIII, in previously treated patients with severe haemophilia A - Coyle, T (Haemophilia, 2012)
(Abstract FP-MO-03.2-3).